For Immediate Release
Gamma Pharmaceuticals Secures Registered Trademark Protection in China
Mr. Hao Zhang, Gamma’s Chief Marketing Officer and China Representative, stated, “We are pleased to have the proper protection for our brands and recourse should there be any infringement. The Chinese nutritional supplement market is growing rapidly and we need to have the correct legal protections as we push our brand identity.”
Gamma has a wholly-owned subsidiary in Hong Kong and a Representative office in Beijing to facilitate its Asian business. Gamma’s three founders have substantial business experience in Asia, having lived and worked there for nearly two decades. Gamma’s management views the rapidly growing Chinese market as a key growth driver for the Company and have budgeted approximately $13 million in revenues for 2010 from the region. Gamma’s intellectual property assets total nearly $6 million on the Company’s balance sheet. Management’s extensive Intellectual Property Management Program is designed to both protect these important assets and to grow their value.
About Gamma Pharmaceuticals Inc
At present Gamma manufactures in North America, and distributes in the United States and China. Gamma’s products utilize proprietary “Gel Delivery Technology®”, to create innovative gel product forms; that give consumers a more pleasant experience. Gel Delivery Technology® characteristics include rapid absorption, convenience and taste great. Market categories Gamma targets are growing as rapidly as 60% per year. Gamma has developed formulas and strategies for Metabolic Syndrome and Diabetes Type II, Stress Reduction, Cognition, Well being, Menopause Symptoms, and Personal Care Products. Gamma also develops and manufactures house brands for major retailers. At this time, Gamma has a total of 36 SKU’s and holds licenses for 9 SKUs in China.
Forward-Looking Statements: This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The statements in this Press Release regarding any impact the quotation of the Company’s stock has on the Pink Sheets or the lack thereof on the OTCBB, and any other effects of the above are forward-looking statements. Such statements are subject to certain risks and uncertainties, and actual circumstances, events or results may differ materially from those projected in such forward-looking statements. The Company cautions readers not to place undue reliance on any forward-looking statements. The Company does not undertake, and specifically disclaims any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur.
Contact: Gamma Pharmaceuticals Inc
Joe Cunningham (jcunningham@gammapharma.com)
Office: (702) 989 5262
Direct: (651) 204 2048